Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of iptacopan in autoimmune benign hematologic disorders
2021-002039-40Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iptacopan in immune thrombocytopenia (ITP), sponsored by Novartis. Started Sep 2021; status: terminated.
02
Drugs
Iptacopan
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2021-002039-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002039-40.